https://scholars.lib.ntu.edu.tw/handle/123456789/579794
標題: | Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV | 作者: | Lee Y.-L. KUAN-YIN LIN Cheng S.-H. Lu P.-L. Wang N.-C. Ho M.-W. Yang C.-J. Liou B.-H. Tang H.-J. Huang S.-S. Huang S.-H. Chen T.-C. Lin C.-Y. Lin S.-P. Lee Y.-T. CHIEN-CHING HUNG Taiwan HIV Study Group |
公開日期: | 2021 | 出版社: | Elsevier B.V. | 卷: | 58 | 期: | 3 | 起(迄)頁: | 106403 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-positive patients with virological failure or intolerance to antiretroviral therapy. Patients receiving DTG plu |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111970673&doi=10.1016%2fj.ijantimicag.2021.106403&partnerID=40&md5=403d5ec5432ddbf9cce8e88921ebae30 https://scholars.lib.ntu.edu.tw/handle/123456789/579794 |
ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2021.106403 | SDG/關鍵字: | dolutegravir; proteinase inhibitor; antiretrovirus agent; dipyrone; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; adult; antiretroviral therapy; antiviral resistance; Article; body weight gain; combination drug |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。